We are witnessing an unprecedented moment in the history of mental health. After decades of stagnation in the development of new treatments, clinical research with psychedelics is producing results that many researchers describe as "unlike anything we have seen before with any psychopharmacological intervention."
Psychedelic-assisted therapy (PAT) is not simply "taking a substance in a clinical setting." It is a specific combination of pharmacology, structured psychotherapy and, above all, integration work. Understanding each of these pieces is essential for approaching this field from evidence rather than myth.
This article covers what we know today: the mechanisms, the data, the real limitations, and the irreplaceable role of integration — especially in the majority context, the one that happens outside clinical trials.
In this article
- What is psychedelic-assisted therapy?
- Mechanisms of action: what happens in the brain
- The main substances and their indications
- Clinical evidence: what the data says
- The clinical framework: preparation, session and integration
- Why integration is everything
- Safety, contraindications and real limits
- The future: regulation, access and what's coming
90% happens outside the clinic
Frequently asked questions
Psychedelic-assisted therapy refers to a set of interventions that combine the controlled administration of psychoactive substances — psilocybin, MDMA, ketamine, LSD, ayahuasca, among others — with a structured psychotherapeutic process before, during and after the experience.
The differentiating element from recreational or spiritual use is precisely that: the structure. A defined clinical framework, a qualified therapeutic team, a clear therapeutic intention and, centrally, an integration process that allows the changes experienced during the session to take root in everyday life.
Important distinction: PAT is not equivalent to psychedelic psychopharmacology. The substance is not the treatment: it is the catalyst. The therapeutic process, before and after the experience, is what transforms an extraordinary experience into real and lasting change.
2. Mechanisms of action: what happens in the brain
The 5-HT2A receptor: the entry point
Classic psychedelics — psilocybin, LSD, DMT — act primarily as agonists of serotonin 5-HT2A receptors on pyramidal neurons of the cerebral cortex. This activation increases neuronal excitability and alters transmission in cortico-thalamic and cortico-cortical circuits, producing the characteristic changes in perception, emotion and sense of self (Kwan et al., 2022; Nichols, 2016; Vollenweider & Smallridge, 2021).
But 5-HT2A is just the beginning of a more complex cascade. The glutamatergic system (AMPA and NMDA receptors), GABAergic system, dopamine and noradrenaline also participate, contributing to changes in excitation/inhibition balance and reward circuits (Vollenweider & Smallridge, 2021; Inserra et al., 2020). A particularly relevant finding: activation of 5-HT2A in the anterior cingulate cortex can potentiate AMPA signalling and promote fear extinction and cognitive flexibility, with direct implications for PTSD and depression treatment (Miranda, 2024).
The default mode network and ego dissolution
One of the most replicated findings in neuroimaging is the reduction of internal connectivity of the Default Mode Network (DMN) under the effect of psychedelics. The DMN is the network associated with autobiographical narrative, self-criticism, rumination and the sense of a separate self. Its deactivation correlates with states of "ego dissolution" that many participants describe as profoundly transformative (Stoliker et al., 2021; Vollenweider & Preller, 2020).
Simultaneously, a decrease in the descending connectivity of the DMN, salience network and executive network toward the amygdala is observed, associated with changes in emotional reactivity under psilocybin (Stoliker et al., 2024). Modulation of ACC–amygdala circuits can reduce fear reactivity and enhance responses to natural rewards (Miranda, 2024).
Neuroplasticity: BDNF, TrkB and mTOR
Here lies perhaps the most relevant finding for understanding why the effects of psychedelics can last weeks or months after a single session.
In the prefrontal cortex, psychedelics promote neuritogenesis, growth of dendritic spines and formation of new synapses, similarly to ketamine (Ly et al., 2018; Knudsen, 2022). These effects depend on activation of BDNF, its receptor TrkB and the mTOR pathway, favouring a "rewiring" of pathological circuits in depression and other disorders (Aleksandrova & Phillips, 2021; Palhas et al., 2025).
A particularly novel finding: LSD and psilocin bind directly to the TrkB receptor with high affinity, and their antidepressant effect requires TrkB but not 5-HT2A. This suggests that the mechanisms of neuroplasticity and hallucination are separable, opening the door to compounds that promote plasticity without intense psychedelic experience (Melani et al., 2025; Vargas et al., 2023).
Another relevant finding: psychedelics activate intracellular 5-HT2A — not just at the membrane — which would explain why they promote plasticity in ways that endogenous serotonin cannot (Vargas et al., 2023; Vollenweider & Preller, 2020).
Inflammation and neuroimmunity
Psychedelics also modulate inflammatory pathways (NF-κB, PI3K/Akt, mTOR) and cytokine profiles, adjusting the balance between neurotoxic and neuroprotective processes. This could contribute to their effects in disorders involving neuroinflammation (Inserra et al., 2020; De Deus et al., 2025).
MDMA and ketamine: different mechanisms
MDMA operates through different pathways: it promotes massive release of serotonin, dopamine and noradrenaline, generating emotional openness, fear reduction and greater capacity to process traumatic memories. Ketamine acts primarily as an NMDA antagonist in the glutamatergic system, producing rapid antidepressant effects — sometimes within hours — through mechanisms that differ substantially from conventional antidepressants.
Summary: Psychedelics produce a combination of acute neuromodulation — immediate changes in networks and circuits — and lasting neuroplasticity — structural reorganisation of synapses. This dual action explains why their effects on mood, cognition and sense of self can be both so rapid and so persistent.
3. The main substances and their indications
Not all psychedelics are the same, nor do they serve the same purpose. Each substance has a distinct pharmacological profile, session duration and context of use.
| Substance | Mechanism | Main indications | Session duration |
|---|---|---|---|
| Psilocybin | 5-HT2A agonist | Treatment-resistant depression, anxiety in terminal illness, addictions | 4–6 hours |
| MDMA | Serotonin/dopamine releaser | PTSD, complex trauma | 6–8 hours |
| Ketamine | NMDA antagonist | Treatment-resistant depression, acute suicidal ideation | 1–2 hours |
| LSD | 5-HT2A agonist | Anxiety, addictions, depression (research) | 8–12 hours |
| Ayahuasca | DMT + MAOIs | Addictions, depression, trauma | 4–6 hours |
Ketamine is currently the only substance approved for clinical use in many countries (intranasal esketamine, FDA-approved since 2019). Psilocybin and MDMA have "breakthrough therapy" designation but no routine approval yet.
4. Clinical evidence: what the data says
The evidence base has grown exponentially over the past decade. The results are promising, the effect sizes are notable, and the methodological limitations are real.
| Condition | Substances | Effect size | Status |
|---|---|---|---|
| Treatment-resistant depression | Psilocybin, MDMA, ketamine | g ≈ 1.9 (psilocybin) | Strong |
| PTSD | MDMA, ketamine | d = 0.91 vs. placebo (MDMA phase 3) | Strong |
| Anxiety / terminal illness | Psilocybin, LSD | Large effects on existential wellbeing | Moderate |
| Alcohol use disorder | Psilocybin, ayahuasca | Preliminary but promising | Emerging |
| Tobacco addiction | Psilocybin | ~80% abstinence at 6 months (Johns Hopkins) | Emerging |
A recent meta-analysis of randomised controlled trials showed a medium-large effect size (Hedges g ≈ 1.21) in PTSD, unipolar depression, anxiety associated with serious illness and social anxiety. These are numbers unusual in the context of mental health research.
However, scientific honesty requires acknowledging the limitations: small samples, difficulty implementing genuine double-blind conditions, high heterogeneity between studies in terms of protocols, and lack of direct comparisons with standard reference therapies.
5. The clinical framework: preparation, session and integration
One of the distinctive characteristics of PAT is its temporal structure. It is not prescribing a pill: it is a process with clearly differentiated phases.
Preparation (1–3 prior sessions) Detailed clinical history, psychoeducation, establishment of therapeutic intention and building the therapeutic alliance. This phase largely determines the quality of the experience.
Substance session (1–3 sessions in a controlled environment) Administration of the substance in a carefully designed environment, with one or two therapists present. The accompaniment is fundamentally non-directive: to hold, not to direct. Music, posture and the physical environment are active parts of the process.
Integration (multiple subsequent sessions, weeks to months) The work of making sense of the experience, anchoring it in everyday life and consolidating changes. This is, according to most clinicians and researchers, the most determining phase for long-term outcomes.
One of the problems identified in the literature is the lack of standardisation: fewer than half of published studies report treatment manuals, specific team training or protocol fidelity verification.
6. Why integration is everything
If there is one conclusion that emerges strongly from clinical research and accumulated practice in this field, it is this: the substance opens a window. Integration decides what happens with what comes through that window.
The psychedelic experience can produce profound insights, significant perceptual reorganisations, contact with blocked emotional material. But without an integration process — psychotherapeutic, somatic, communal, creative or contemplative — these insights tend to fade, fail to translate into real changes or, in some cases, generate unresolved confusion.
What is psychedelic integration? The process — continuous and non-linear — of making sense of what was experienced, incorporating it into personal narrative and translating it into concrete changes in how we relate to ourselves, to others and to life. It has no expiry date.
The most commonly used therapeutic frameworks in integration include Acceptance and Commitment Therapy (ACT), Internal Family Systems (IFS), body-based mindfulness (MBSR, Somatic Experiencing), Compassion Focused Therapy and existential psychotherapy.
Community integration — peer accompaniment, practice groups, integration circles — is gaining recognition as a valuable complement. It does not replace professional therapeutic work, but offers something the clinic rarely can: continuity, belonging and the mirror of similar experiences.
7. Safety, contraindications and real limits
The narrative around psychedelics oscillates between two equally distorted extremes: the demonisation inherited from drug policies of the 1970s and the miraculous promise of some current wellness discourses. Science is at neither extreme.
In recent clinical trials, the safety profile of classic psychedelics in controlled settings is favourable: good tolerability, few serious adverse events and no clear signals of abuse or dependence in therapeutic contexts. However, the risks exist:
- Difficult experiences ("bad trips"): can occur even in clinical settings, especially with high doses or in people with unprocessed emotional material.
- Risk of decompensation in vulnerable populations: people with a history of psychosis or bipolar disorder type I are generally excluded from trials due to risk of decompensation.
- HPPD: rare but documented phenomenon in which altered perceptions persist after the experience.
- Drug interactions: particularly relevant with serotonergic antidepressants (risk of serotonin syndrome with MDMA).
- Framework problems: studies on harms document cases of boundary violations when the containment framework is inadequate or the team is insufficiently trained.
The conclusion is not that psychedelics are inherently dangerous, but that context — set, setting and accompaniment — is not an optional complement. It is the fundamental safety variable.
8. The future: regulation, access and what's coming
The regulatory landscape is changing, though more slowly than media coverage suggests. The FDA has requested additional phase 3 data for MDMA before making a decision. In Europe, the landscape is heterogeneous: the Netherlands, Switzerland and Belgium have more permissive frameworks for research or compassionate access.
The priorities the scientific community identifies for the coming years:
- Larger trials, with greater participant diversity and direct comparisons between substances and with standard therapies.
- Protocol standardisation: treatment manuals, training programmes and fidelity verification.
- Mechanisms research: neuroimaging, biomarkers, neuroplasticity as mediating variables.
- Exploration of psychedelic-inspired "non-hallucinogenic" formulations that promote neuroplasticity without intense subjective experience.
- Scalable and equitable access models, given that current clinical programme costs (between €990 and €4,500) make them inaccessible to most people.
9. 90% happens outside the clinic: the integration gap
There is one piece of data that any honest conversation about this field must include: 90% of psychedelic use happens outside clinical settings, without structured preparation and without integration support.
This is not an argument against psychedelics. It is an argument for integration as a public health practice. Thousands of people across Europe and beyond are having psychedelic experiences — with mushrooms, truffles, ayahuasca, LSD — without any support framework to process what arises.
Research suggests that unintegrated psychedelic experiences can result in prolonged confusion, difficulty functioning, or simply the loss of real transformative potential.
"Psychedelic integration should not be a privilege reserved for those who can pay thousands of euros for clinical programmes. It is a public health necessity." — Psyflow
At Psyflow, we have built a structured, accessible and evidence-based integration programme, specifically to accompany people who have had or will have psychedelic experiences outside the clinical context. A free 10-week programme, built on the Buddhist principle of dāna, combining meditation, somatic work, IFS, ACT, MBSR and community.
Because healing should not depend on the size of your wallet.
10. Frequently asked questions
Is psychedelic-assisted therapy legal in the UK, US or Europe?
The legal landscape varies significantly by country. In the US, psilocybin and MDMA have FDA "breakthrough therapy" designation but are not yet routinely approved. Oregon and Colorado have legalised supervised psilocybin use. In the UK, both substances remain Schedule 1. In Europe, Switzerland and the Netherlands have more permissive frameworks for research and compassionate access. Ketamine is approved for clinical use in many countries as intranasal esketamine for treatment-resistant depression.
How much does a psychedelic-assisted therapy programme cost?
Private clinical psychedelic-assisted therapy programmes currently cost between €990 and €4,500 (approximately £850–£3,900 or $1,000–$5,000), depending on the country, substance and number of sessions. The lack of insurance coverage and high cost are among the main access barriers the field needs to address.
What is the difference between psychedelic therapy and psychedelic integration?
Psychedelic therapy involves the administration of the substance in a controlled clinical setting with a qualified therapeutic team. Psychedelic integration is the process of making sense of a psychedelic experience — clinical or not — and translating it into real changes in everyday life. Integration can be done without access to a clinical programme, and in fact most people who use psychedelics need integration support without having access to formal therapy.
Is it safe to use psychedelics without clinical supervision?
Risks increase significantly outside a controlled framework. Without prior assessment, without accompaniment during the experience and without integration afterwards, the potential for harm is greater: difficult experiences without containment, activation of traumatic material without support, or loss of the transformative potential of the experience. Context — set, setting and accompaniment — is the most important safety variable, not the substance itself.
What conditions have the strongest evidence for psychedelic therapy?
The indications with the strongest current evidence are treatment-resistant depression — especially with psilocybin, with effect sizes of g ≈ 1.9 — and PTSD, with MDMA showing d = 0.91 versus placebo in phase 3 studies. There is moderate evidence for anxiety associated with terminal illness, and emerging evidence for alcohol and tobacco addiction.
What is psychedelic integration and how can I access it?
Psychedelic integration is the continuous, non-linear process of making sense of what was experienced in a psychedelic state and incorporating it into daily life. It can take the form of individual psychotherapy, integration groups, somatic practice, meditation or creative work. At Psyflow we offer a free, structured, evidence-based 10-week integration programme available in Spanish and English, built on the Buddhist principle of dāna: open access, voluntary contribution.
References
Aleksandrova, L. & Phillips, A. (2021). Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends in Pharmacological Sciences. · Carhart-Harris, R. et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine. · De Deus, J. et al. (2025). Psychedelics in neuroinflammation: Mechanisms and therapeutic potential. Progress in Neuro-Psychopharmacology & Biological Psychiatry. · Inserra, A. et al. (2020). Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. Pharmacological Reviews. · Keltner, D. & Haidt, J. (2003). Approaching awe, a moral, spiritual, and aesthetic emotion. Cognition & Emotion. · Knudsen, G. (2022). Sustained effects of single doses of classical psychedelics in humans. Neuropsychopharmacology. · Krediet, E. et al. (2020). Reviewing the potential of psychedelics for the treatment of PTSD. International Journal of Neuropsychopharmacology. · Kwan, A. et al. (2022). The neural basis of psychedelic action. Nature Neuroscience. · Levine, P. (2010). In an Unspoken Voice. North Atlantic Books. · Ly, C. et al. (2018). Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports. · Melani, A. et al. (2025). Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications. Pharmaceuticals. · Miranda, L. (2024). Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex. Brain Research. · Mitchell, J. et al. (2021). MDMA-assisted therapy for severe PTSD. Nature Medicine. · Neff, K. & Germer, C. (2013). A pilot study and randomised controlled trial of the mindful self-compassion program. Journal of Clinical Psychology. · Nichols, D. (2016). Psychedelics. Pharmacological Reviews. · Palhas, M. et al. (2025). Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics. Progress in Neuro-Psychopharmacology & Biological Psychiatry. · Stoliker, D. et al. (2021). Neural Mechanisms and Psychology of Psychedelic Ego Dissolution. Pharmacological Reviews. · Stoliker, D. et al. (2024). Neural Mechanisms of Resting-State Networks and the Amygdala under Psilocybin. Biological Psychiatry. · Van Elk, M. & Yaden, D. (2022). Pharmacological, Neural, and Psychological Mechanisms underlying Psychedelics. Neuroscience & Biobehavioral Reviews. · Vargas, M. et al. (2023). Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. · Vollenweider, F. & Preller, K. (2020). Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience. · Vollenweider, F. & Smallridge, J. (2021). Classic Psychedelic Drugs: Update on Biological Mechanisms. Pharmacopsychiatry.
